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Abstract
Background: Radical treatment for oligometastatic non-small-cell lung cancer (NSCLC) has a curative potential for
selected patients. The present retrospective study was designed to examine the relevance of synchronous vs.
metachronous manifestations as a potential prognostic factor when ablative treatments are performed in
oligometastatic disease.
Methods: Seventy-five patients with radically treated oligometastatic NSCLC were identified, of whom 39 presented
with synchronous and 36 with metachronous metastatic manifestations. For patients with synchronous metastases,
an additional therapy of the thoracic locoregional disease with a curative intent (either surgery or
radiochemotherapy) was required. All patients with metachronous metastases had a documented remission of the
primary tumor. Ablative treatment of the complete extent of oligometastatic disease consisted (as a minimum
requirement) of either complete surgical resection or definitive ablative stereotactic radiotherapy. A comparative
survival analysis of two groups of patients with oligometastatic NSCLC (synchronous vs. metachronous) and a
complementary analysis of prognostic factors for the whole group of patients (by means of Cox regression analysis)
was performed. Endpoints were median overall and progression-free survival (OS, PFS, respectively).
Results: Of the 75 patients, 57 presented with a solitary metastasis, in only 7 patients metastastatic lesions were
present in ≥2 organs and 66 patients had a Karnofsky performance score (KPS) of 80 % or 90 %. The median
follow-up was 54.0 months (95 % CI 28–81), the median OS 21.8 months (16.1–27.6) and the median PFS 13.
7 months (9.7–17.6). In univariable Cox regression analysis, no single clinical factor was significantly associated with
OS. For PFS both ‘metastatic involvement of ≥2 organs vs. 1 organ’ (hazard ratio (HR) 0.43, 0.23–0.83, p = 0.012) and
a ‘KPS of 90 % vs. 70–80 %’ (HR 4.32, 1.73–10.89, p = 0.02) were significant prognostic factors as calculated by
multivariable analysis. Comparing the cohorts with synchronous (n = 39) vs. metachronous oligometastases (n = 36),
no differences in median OS and PFS were found. Both cohorts were well-balanced except for the KPS, which was
significantly superior in patients with synchronous oligometastases.
Conclusions: Radical treatment of oligometastatic NSCLC was associated with acceptable long-term survival rates
in patients with good KPS and it was equally effective for synchronous and metachronous manifestations.
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Background
Since its introduction by Hellman and Weichselbaum in
1995 [1] the concept of ‘oligometastatic disease’ has
gained clinical relevance [2]. Meanwhile, most metastatic
lesions inside or outside the brain are amenable to an in-
creasing variety of ablative therapeutic modalities, be it
surgery, stereotactic ablative (intra- or extracranial)
radiotherapy, or radiofrequency or microwave ablation.
For non-small-cell lung cancer (NSCLC) – as is the case
for most entities of malign solid tumors – the state of
oligometastatic disease has not yet been adopted as a
discrete, single category in the AJCC staging system.
Nevertheless, aggressive local treatment for limited site
oligometastic disease is recommended in the current
version of NCCN-guidelines, where it is yet confined to
brain and adrenal involvement (http://www.nccn.org/
professionals/physician_gls/pdf/nscl.pdf ). From the large
number of retrospective trials it may be inferred that, at
least in specialized centers, radical treatment approaches
for oligometastases are widely used. A recent metaanalysis
of aggressive treatment of oligometastatic NSCLC based
on 757 individual patient data revealed several prognostic
factors [3]. Among other determinants, a significantly
worse outcome in overall survival for synchronous as op-
posed to metachronous appearance of oligometastases
was reported in that metaanalysis. This was especially the
case for patients with concurrent N1/N2 disease. Thus,
the role of curative approaches in synchronous oligometa-
static NSCLC seems to be questionable.
The presented retrospective analysis of a group of 75
patients with oligometastatic NSCLC was designed to
examine potential predictive factors for long-term survival
outcome of radical treatments (including innovative
contemporary irradiation technology) in terms of OS and
PFS and as an in-depth analysis opposing synchronous to
metachronous metastases.
Methods
Study population and inclusion criteria
The patient database of the Department for Radiotherapy
and Radiation Oncology, Saarland University Medical
Center, was screened for patients with histologically con-
firmed NSCLC who had presented with oligometastatic
disease at the time of initial diagnosis (‘synchronous’) or
had oligometastatic recurrence during the course of
disease at least three months after the initial diagnosis
(‘metachronous’). Only patients with ≤5 metastases (≤3
brain metastases) were included and radical treatment for
all metastases was mandatory, i.e. either complete resection
of the metastastic lesion ± adjuvant radiotherapy or defini-
tive radiotherapy to the metastatic lesion with a biologically
effective dose for α/β = 10 Gy (BED10) of ≥60 Gy. Addition-
ally, the thoracic locoregional tumor in patients with syn-
chronous manifestations had to be treated with a curative
scheme according to the current standard of care (either
complete resection with or withouth adjuvant/neoadjuvant
chemotherapy/radiotherapy or definitive concurrent ra-
diochemotherapy with at least 60 Gy, conventional frac-
tionation, and a platinum-based chemotherapy). For
the cohort with metachronous metastases, a controlled
locoregional disease was required as documented by a
computed tomography of the chest. Seventy-five pa-
tients were identified, who met all prerequisites and re-
ceived treatment between March 2000 and April 2015
(55 of these patients (73 %) received treatment between
2008 and 2015).
Primary endpoints were overall survival (OS) and
progression-free survival (PFS). For patients with syn-
chronous metastases, survival data were calculated
from the day of first treatment of either the primary tumor
or metastatic lesions and for patients with metachronic
metastases from the day of first treatment of oligometa-
static disease.
Statistical analysis
Differences in baseline characteristics between synchron-
ous and metachronous oligometastatic disease groups
regarding categorical variables were assessed using the
chi-squared test or Fisher’s exact test (for 2x2 tables)/
Fisher-Freeman-Halton test (for RxC tables). Statistical
differences concerning continuous variables were exam-
ined using the two-sample t-test (for normal distributions).
All applied statistical tests were two-sided, and a p-value
less than 0.05 was considered statistically significant. Uni-
variable Cox proportional hazard models were performed
to assess predictive factors associated with OS and PFS. Fi-
nally, statistically significant predictors from univariable
analyses were used in multivariable analyses with a forward
selection procedure. As predictor variables we selected age
(>60 vs. ≤ 60 years); sex; KPS (90 % vs. 70–80 %); weight
loss (≤5 % vs. >5 %); ‘metachronous’ vs. ‘synchronous’ oli-
gometastases; histology (squamous vs. adenocarcinoma);
T-stage (T3/T4 vs. T1/T2); N-Stage (N2/3 vs. N0/N1);
Thoracic UICC stage (III vs. II/I); localization of metastases
(other vs. brain); number of metastases (≥2 vs. 1); number
of involved organs (≥2 vs. 1); treatment of primary tumor
(without vs. with surgery); treatment of oligometastases
(radiotherapy vs. surgery); FDG-PET based staging;
additional chemotherapy.
Kaplan-Meier estimates were calculated for (median)
OS and (median) PFS. Differences between strata were
calculated by use of log-rank test. All statistical tests
were performed with SPSS statistics version 23 (IBM
Corporation, Armonk, NY).
Results
The patient characteristics are presented in Table 1. The
included patients had predominantly favorable baseline
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Table 1 Patient characteristics
All Synchronous Metachronous p
Total no. of patients 75 39 36
Age, years
mean ± SD 59.1 ± 8,4 59.5 ± 9,1 58.5 ± 7,6 0.63b
range 39-77 39-77 42-77
Sex, no. (%)
Male 43 (57) 23 (59) 20 (56) 0.76c
Female 32 (43) 16 (41) 16 (44)
KPS, no. (%)
70 9 (12) 3 (8) 6 (17)
80 38 (51) 14 (36) 24 (66) 0.002d
90 28 (37) 22 (56) 6 (17)
Weight loss, no. (%)
<5% 65 (87) 36 (92) 29 (81) 0.18e
>5% 10 (13) 3 (8) 7 (19)
Histology
Adenocarcinoma 50 (67) 26 (67) 24 (66)
Squamous 17 (23) 9 (23) 8 (22) 1.0d
Other 8 (10) 4 (10) 4 (11)
T-Stagea, no. (%)
T1 11 (15) 3 (8) 8 (22)
T2 37 (50) 21 (54) 17 (47) 0.36c
T3 12 (16) 7 (18) 5 (14)
T4 14 (19) 8 (20) 6 (17)
N-Stagea, no. (%)
N0 28 (38) 10 (25) 19 (53)
N1 14 (19) 7 (18) 7 (19) 0.06d
N2 28 (38) 19 (49) 9 (25)
N3 4 (5) 3 (8) 1 (3)
Thoracic UICC stage, no. (%)
IA 4 (5) 1 (3) 3 (8)
IB 7 (9) 4 (10) 3 (8)
IIA 14 (19) 6 (15) 9 (25) 0.08d
IIB 10 (14) 2 (5) 8 (22)
IIIA 25 (34) 17 (44) 8 (22)
IIIB 14 (19) 9 (23) 5 (14)
Localization of metastases, no. (%)
Brain 51 (62) 26 (59) 25 (65)
Bone 7 (8) 5 (11) 2 (5)
Lung 9 (11) 5 (11) 4 (11)
Lymphatic 5 (6) 4 (9) 1 (3) 0.16d
Adrenal Gland 3 (4) 3 (7) 0
Soft tissue 3 (4) 0 3 (8)
Other 4 (5) 1 (2) 3 (8)
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criteria: the majority of patients (88 %) had a good Kar-
nofsky performance score (KPS) of 80 % or 90 % and
most patients suffered no weight loss prior to the ana-
lyzed treatment (87 %). Oligometastatic disease was
mostly limited: 91 % of patients had metastases confined
to one involved organ and 76 % of patients presented
with a solitary metastasis. Brain metastases outweighed
all other involved metastastic sites. Three patients with
adenocarcinoma histology had a mutation of the epider-
mal growth factor receptor and received additional treat-
ment with erlotinib. Patients were additionally stratified
according to either synchronous or metachronous occur-
rence of oligometastases. Both groups were well bal-
anced with respect to most clinical criteria (the only
exemption was KPS, which was significantly superior in
patients with synchronous occurrence of metastases).
For patients with metachronous metastases, the median
interval between the first diagnosis of NSCLC and detec-
tion of oligometastatic disease was 15.2 months (range
3–58 months), which may diminish the impact of the
modality of the earlier treatment of the primary tumor
in this subgroup.
As to survival analysis, the median follow-up of all pa-
tients was 54.0 months (interquartile range (IQR) 52.5),
the median follow-up for patients with synchronous oligo-
metastases was 39.1 months (IQR 52.5) and for patients
with metachronous oligometastaes 59.9 months (IQR
131.9), respectively. An actual number of 8 patients
survived for more than 5 years and 47 patients have died
during the examined follow-up period. The median OS
for all patients was 21.8 months (95 % CI 16.1–27.6) and
the PFS was 13.7 months (9.7–17.6) (Fig. 1). The actuarial
1-year-, 2-year- and 5 year-OS rates were 78 % , 44 % and
27 % 6 % with standard errors of 5 %, 6 % and 6 %, re-
spectively. The corresponding 1-year-, 2-year- and 5 year-
PFS rates were 50 % , 26 % and 11 % with standard errors
of 5 %, 6 % and 6 %, respectively. For a variety of clinical
factors, which may impact OS and PFS a univariable cox
regression analysis was performed (Table 2). Most import-
antly, no statistically significant differences – with and
without adjustment for KPS – between patients with syn-
chronous and metachronous occurrence of oligometastases
were observed concerning OS (p = 0.43) or PFS (p = 0.15;
see Fig. 1). Also, none of the other examined factors
Table 1 Patient characteristics (Continued)
No. of metastases, no. (%)
1 57 (76) 29 (74) 28 (78)
2 11 (15) 6 (15) 5 (14) 1.0d
3–5 7 (10) 4 (10) 3 (8)
No. of involved organs, no. (%)
1 68 (91) 34 (87) 34 (95) 0.43e
> 2 7 (9) 5 (13) 2 (5)
Treatment of primary tumor, no. (%)
Surgery ± (neo)adjuvant RT and/or CT 55 (73) 26 (66) 29 (80)
RCT 18 (24) 12 (31) 6 (17) 0.34d
SBRT 2 (3) 1 (3) 1 (3)
Treatment of oligometastases, no. (%)
Surgery 12 (14) 7 (16) 5 (13)
SRS/hSRT/SBRT 19 (23) 10 (22) 9 (23) 0.88d
Surgery/RT combined 49 (58) 25 (56) 24 (61)
cf-RT 4 (5) 3 (7) 1 (3)
FDG-PET based staging, no. (%) 51 (68) 34 (87) 17 (47)
Additional chemotherapy, no. (%) 48 (64) 27 (69) 21 (58)
FEV1, % predicted
mean ± SD 76 ± 24 77 ± 27 74 ± 20 0.20b
SD standard deviation, RT radiotherapy, CT chemotherapy, RCT radiochemotherapy, SBRT stereotactic body radiotherapy, SRS stereotactic radiosurgery, hSRT
hypofractionated stereotactic radiosurgery, cf-RT conventionally fractionated radiotherapy, KPS Karnofsky Performance Score, FEV1 Forced expiratory volume
during 1st second of breathing maneuver
arefers to initial staging also for patients with metachronous metastases
bf-test for unpaired samples was used
cchi-square test was used
dFisher-Freeman-Halton test was used
eFisher's exact test was used
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were associated with OS in univariable analysis. How-
ever, three variables had a significant impact on PFS in
univariable analysis: first, KPS, second, the presence of
brain involvement and third, the limitation of oligome-
tastatic spread to one organ. These three factors were
subsequently examined via multivariable cox regression
analysis. Here, a KPS of 90 % vs. 70–80 % (hazard ratio
[HR] 0.43, 0.23–0.83, p = 0.012) and the metastastic in-
volvement of more than one organ (HR 4.32, 1.73 – 10.89,
p = 0.02) remained significant, whereas the presence of
brain involvement did not.
The examined patients received a diversity of radical
treatment schemes for oligometastases. Sixty-three out
of 75 patients received radiotherapy, but only 23
patients received radiotherapy alone to metastatic sites.
A majority of 49 patients underwent a combination of
surgery and radiotherapy, of whom 37 patients had
either whole brain radiotherapy or stereotactic radio-
therapy as adjuvant treatment after resection of brain
metastases.
Raw data of the patients’ characteristics and survival are
included as an additional file (Additional file 1: raw_data).
Fig. 1 Overall survival (a) and progression-free survival (c) for all patients and stratified by synchronous vs. metachronous occurrence of oligometastic
disease (b, d). The vertical markings indicate censored patients. The x-axis is capped at 121 months follow-up in all graphs, as in all groups two or less
patients underwent a follow-up exceeding the presented interval
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Discussion
The favorable survival data of the analyzed group of 75
patients (median OS 21.8 months) support the assump-
tion that oligometastatic NSCLC constitutes a category
of its own. In accordance with other retrospective ana-
lyses of radical treatment of oligometastic NSCLC [3] we
found that this aggressive approach was mainly pursued
in patients who had a good KPS and who were 10 years
younger than the average German patient at the time of
first diagnosis of lung cancer [4]. Interestingly, median
OS of oligometastatic disease in these selected patients
does not seem to be inferior to that of patients with inoper-
able stage III NSCLC, in whom it averages 21 months [5].
A multitude of single factors may influence the efficacy of
Table 2 Univariable cox regression analysis of clinical factors potentially associated with overall survival (OS) and progression free
survival (PFS)
OS PFS
Univariable HR (95 % CI) p Univariable HR (95 % CI) p
Age, years
>60 vs. S 60 1.25 (0,70-2,23) 0.44 1.10 (0,65-1,85) 0.72
Sex
Female vs. male 1.19 0.66-2.13) 0.57 1.00 (0.59-1.69) 0.99
KPS
90 % vs. 70–80% 0.68 (0.37-1.24) 0.21 0.51 (0.29-0.89) 0.018
Weight loss
S 5 % vs. > 5 % 0.78 (0.31-1.99) 0.60 1.18 (0.53-2.63) 0.69
M1-stage - time of occurence
Metachronous vs. synchronous 1.26 (0.71-2.24) 0.43 1.46 (0.87-2.48) 0.15
Histology
Squamous vs.Adeno. 0.64 (0.28-1.46) 0.29 0.75 (0.37-1.50) 0.42
T -Stagea
T3/T4 vs. T1/T2 0.79 (0.41-1.52) 0.29 1.02 (0.59-1.79) 0.94
N-Stagea
N2/N3 vs.N0/N1 1.27 (0.71-2.25) 0.43 1.26 (0.74-2.15) 0.40
Thoracic UICC stage
II vs. I 2.28 (0.87-5.96) 0.09 3.80 (1.36-10.69) 0.011
III vs. I/II 0.85 (0.48-1.51) 0.59 0.84 (0.49-1.43) 0.53
Localization of metastases
Other vs. Brain 0.80 (0.43-1.51) 0.50 0.48 (0.26-0.91) 0.024
No. of metastases
> 2 vs. 1 1.10 (0.56-2.17) 0.79 1.26 (0.71-2.26) 0.43
No. of involved organs
> 2 vs. 1 1.03 (0.32-3.33) 0.96 2.90 (1.30-6.46) 0.009
T reatment of primary tumor
Without vs. with Surgery 1.58 (0.74-3.40) 0.24 1.07 (0.58-1.96) 0.84
T reatment of oligometastases
SRS/hSRT/SBRT vs. Surgery 1.00 (0.36-2.84) 0.99 0.75 (0.29-1.95) 0.55
FDG-PET based staging
PET vs. no PET 1.00 (0.54-1.84) 1.00 0.84 (0.48-1.47) 0.54
Additional chemotherapy
CT vs. no CT 0.69 (0.39-1.23) 0.21 0.84 (0.49-1.44) 0.52
SD standard deviation, RT radiotherapy, CT chemotherapy, RCT radiochemotherapy, SBRT stereotactic body radiotherapy, SRS stereotactic radiosurgery, hSRT
hypofractionated stereotactic radiosurgery, cf-RT conventionally fractionated radiotherapy, KPS Karnofsky Performance Score
arefers to initial staging also for patients with metachronous metastases
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radical treatment in oligometastatic disease and therefore
survival. A recently published metaanalysis of 757 patients
(the data were mostly derived from non-randomized retro-
spective trials) revealed synchronous (vs. metachronous)
metastases, N1 or N2-stage (vs. N0) and ‘non-adenocarcin-
oma’ as being predictive for a decreased OS (as calculated
in multivariable analyses). For patients with synchronous
oligometastases the categories ‘surgery for the primary lung
tumor’ and ‘smaller radiotherapy planning target volume’
were found to be predictive for improved OS in the ana-
lysis of Griffioen et al. [6], whereas the absence of nodal
mediastinal involvement, adenocarcinoma, tumor size of
<3 cm and age of <59 years were associated with improved
OS in the study of Mordant et al. [7].
In the present study we specifically address the rele-
vance of synchronous vs. metachronous metastases, be-
cause a thorough baseline stratification according to this
variable had not been reported beforehand. The category
‘synchronous vs. metachronous’ discriminates two vastly
different clinical scenarios: in patients with synchronous
oligometastatic NSCLC most often a significant tumor
burden is present and treatment of the metastatic site
and multimodal treatment of the primary tumor have to
be integrated in a reasonable manner. In comparison,
treatment of patients with metachronous oligometas-
tases and lasting local tumor control is confined to abla-
tive therapy of the metastatic site and usually second
line chemotherapy, whereas the applied initial therapy
may generally limit therapeutic options. Considering this
backdrop, the two groups of the present analysis were
well balanced with respect to all baseline and treatment
criteria (even though significant, the differences in KPS
were small by an absolute measure). As we could not
demonstrate significant differences in OS and PFS be-
tween synchronous and metachronous oligometastatic
disease and no relevant selection bias was present be-
tween these groups, both of them seem equally qualified
for radical treatment strategies.
It can be assumed that for patients with synchronous
metastases local control of the primary tumor is at least
as important for long-term survival as control of meta-
static sites. The OS of patients with synchronous oligo-
metastic disease compares favorably to the results
reported in the Dutch prospective phase II trial [8]. In
that trial, 39 patients with synchronous oligometastatic
NSCLC received radical treatment, but all of these pa-
tients had definitive radio(chemotherapy) as the treat-
ment of the primary tumor (in the present study 73 % of
patients underwent thoracic surgery). Although only
two patients had a local recurrence, the median overall
survival (OS) was only 13.5 months (7.6–19.4). Guerra
et al. reported a series of 78 patients with oligometa-
static NSCLC who received chemoradiation to the pri-
mary site, but only 44 patients received additional
radical local treatment of the metastases [9]. On multi-
variable analysis, they found an improved OS for pa-
tients, who were treated with 63 Gy or more of
radiation to the primary site, who had a KPS >80 %,
and who exhibited smaller tumor volumes, whereas
whether or not oligometastatic disease was radically
treated did only impact OS for the subset of patients
with brain metastases. Su et al. also reported a survival
benefit with radiotherapy of >63 Gy to the primary
tumor in 93 patients with stage IV NSCLC, many of
whom had multiple metastases [10].
Iyengar et al. reported favorable results for 24 patients
with stage IV NSCLC and predominantly extracranial me-
tastases, who experienced disease progression after first-
line chemotherapy and were subsequently treated with
stereotactic body radiation therapy (SBRT) to all involved
sites in addition to erlotinib [11]. From the initiation of
salvage SBRT + erlotinib median PFS was 14.7 months
and median OS 20.4 months for these patients.
Due to the lack of prospective randomized studies,
the added benefit of radical treatment of oligometas-
tases remains unclear, although the strategy is sup-
ported by favorable survival data in comparison to
historic data.
The sample size of the presented analysis is small from
a statistical perspective, even though, with 75 analyzed
patients, we could gather the second largest monoinsti-
tutional data pool in comparison with the recent metaa-
nalysis [3]. Certainly, the present study has some further
limitations: first, the analyzed group of patients is in-
homogeneous with respect to locoregional tumor extent,
the involvement of metastatic sites, the number of me-
tastases and the applied treatments; second, it is retro-
spective and therefore may contain inaccuracies with
respect to the documentation of tumor progression
dates (with a proportion of patients who needed to be
censored in PFS survival analysis); and third, FDG-PET-
staging was more frequently used in patients with syn-
chronous vs. metachronous disease (87 % vs. 47 %),
which may have impacted staging accuracy in the latter
group. The majority of patients had brain metastases
(62 %). Even though no impact of the involved metastatic
site on survival was found, the number of examined
patients is too small to perform a reliable comparison
between different sites.
Conclusions
The presented favorable survival data both in synchronous
and metachronous oligometastatic NSCLC encourage the
use of an aggressive, ablative therapy for selected patients.
The actual benefit of radical therapy of metastatic sites
has yet to evaluated in prospective randomized trials. Syn-
chronous vs. metachronous manifestation of metastases
was not of prognostic relevance in the examined cohort.
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